LX214

**LX214** is a topical ophthalmic solution formulation of **voclosporin**, a next-generation calcineurin inhibitor, developed by Lux Biosciences using proprietary mixed nanomicellar technology to enable sustained 24-hour drug levels in the eye. It acts by inhibiting calcineurin to suppress T-cell activation and reduce ocular inflammation, targeting chronic inflammatory eye diseases. Primarily investigated as a potential best-in-class treatment for **dry eye syndrome** (keratoconjunctivitis sicca), with Phase 1 trials showing good tolerability at 0.02% and 0.2% doses and open-label efficacy signals; additional targets included blepharitis and atopic keratoconjunctivitis.[1][3][4][5]